Marc-Andre Kasper
Vice President, Chemistry & Early Discovery Tubulis GmbH
Seminars
Wednesday 18th March 2026
Matched Conjugation Platforms Unlock the Therapeutic Potential of Heterobifunctional Degrader-Antibody Conjugates Through mAb-like Pharmacokinetics at High DAR and Excellent In Vivo Efficacy
8:00 am
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Here we present novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders
- Resulting DACs are homogenous with high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy
Tuesday 17th March 2026
Designing Linker Technologies & Conjugation Approaches that Support the Unique Properties of Novel Payloads & Targeting Formats
1:00 pm
This workshop explores the latest approaches to tuning linker performance and conjugation chemistry for ADCs, degraders, peptides, and oligonucleotide conjugates — helping teams engineer reliable, reproducible constructs that translate successfully to the clinic.
- Exploring linker stability, cleavability, and compatibility with degraders, oligos, and peptides
- Addressing conjugation challenges with non-traditional payloads and formats (e.g. enzymatic vs. chemical conjugation)
- Case studies on linker selection for tissue-specific delivery and overcoming off-target toxicity
- Identify future directions in cleavable, condition-responsive, and bioorthogonal linker systems
